Becker's ASC

Are Multiple-Dose Vials as Safe as Single-Dose Vials If Drawn With Aseptic Technique: Q&A With Dr. Clifford Gevirtz

The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
Seeking Alpha

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
Nasdaq

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
Targeted Oncology

Comfort With Dose Reduction of Myeloma Bispecific Depends on Response

The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...
Nasdaq

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog

Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...